Behind every shocking headline about addiction, from the millions caught in the grip of prescription painkillers to the billions lost in economic fallout, lies a complex human story written in statistics like these.
Key Takeaways
- In 2022, 70.4 million people aged 12 or older (24.9% of the U.S. population) reported past year misuse of prescription pain relievers
- Globally, 296 million people used cannabis in 2021, representing 5.8% of the adult population aged 15-64
- In the United States, 48.7 million people aged 12 or older (17.3%) used illicit drugs in the past year in 2022
- Fentanyl-involved overdose deaths rose 22% from 2021 to 2022, totaling 73,838 in the U.S.
- Opioid use disorder led to 81,806 overdose deaths in the U.S. in 2022
- Methamphetamine-involved overdose deaths increased to 36,466 in the U.S. in 2022
- Illicit drug use costs the U.S. $740 billion annually in healthcare, crime, and lost productivity
- Opioid crisis economic burden: $1.02 trillion in U.S. from 2015-2020
- Alcohol misuse costs U.S. $249 billion yearly in healthcare and lost productivity
- 28.3 million people aged 12+ had substance use disorder in U.S. 2022
- Only 21.2% of people with opioid use disorder received medications for addiction in 2021
- Methamphetamine use disorder treatment completion rate: 40-60% with contingency management
- U.S. federal drug arrests totaled 1.2 million in 2022, mostly possession
- 42 U.S. states legalized medical cannabis by 2023, covering 93% population
- DEA Schedule I drugs include heroin, LSD, marijuana, ecstasy per Controlled Substances Act
Millions of people misuse substances globally, resulting in addiction and death.
Addiction and Treatment
- 28.3 million people aged 12+ had substance use disorder in U.S. 2022
- Only 21.2% of people with opioid use disorder received medications for addiction in 2021
- Methamphetamine use disorder treatment completion rate: 40-60% with contingency management
- Alcohol use disorder remission rate: 36% within one year with treatment
- Cocaine addiction recovery: 50% relapse within 1 year post-treatment
- Heroin users entering treatment: average 7 years of use prior
- Buprenorphine treatment reduces opioid overdose risk by 38%
- Cannabis use disorder affects 10% of regular users, 16% of daily users
- U.S. behavioral health treatment facilities: 17,581 serving 5 million annually
- Nicotine addiction treatment success: 25-30% long-term quit rate with varenicline
- MDMA-assisted therapy for PTSD: 67% remission rate in phase 3 trials
- Inhalant addiction recovery challenging, with 50% relapse in first month
- Kratom withdrawal similar to opioids, treated with buprenorphine in 70% cases
- LSD tolerance develops rapidly, but psychological dependence low at 5%
- Contingency management boosts stimulant treatment retention by 50-100%
- MAT for alcohol (naltrexone) reduces heavy drinking days by 25%
Addiction and Treatment Interpretation
These statistics paint a stark picture of a nation struggling with addiction, where proven treatments like medication and contingency management are woefully underutilized lifelines that we must urgently extend to more people.
Economic Costs
- Illicit drug use costs the U.S. $740 billion annually in healthcare, crime, and lost productivity
- Opioid crisis economic burden: $1.02 trillion in U.S. from 2015-2020
- Alcohol misuse costs U.S. $249 billion yearly in healthcare and lost productivity
- Methamphetamine economic impact: $23.4 billion annually in U.S. healthcare and crime
- Cocaine production and trafficking generate $88 billion in global illicit revenue yearly
- U.S. prescription opioid misuse costs $78.5 billion per year in healthcare alone
- Global cannabis market illicit value: $75 billion annually
- Heroin-related crime costs U.S. $50 billion annually in enforcement and victimization
- Treatment for substance use disorders costs U.S. $42 billion yearly
- Lost productivity from drug use disorders: 194 million lost workdays in U.S. annually
- Fentanyl crisis adds $1,500 per capita healthcare cost in high-burden U.S. states
- Global amphetamines trafficking revenue: $40 billion per year
- MDMA/ecstasy market value: $5-10 billion globally illicit sales annually
- Inhalant-related emergency visits cost U.S. $2.5 billion yearly
- Kratom-related hospitalizations cost $50 million annually in U.S.
- Workplace drug testing saves U.S. employers $1 billion yearly in accident prevention
- U.S. spends $15 billion annually on drug-related incarceration
Economic Costs Interpretation
America's addictions are essentially running a monstrous, trillion-dollar shadow economy where the only products are ruin, the only growth is in suffering, and every citizen is an unwitting shareholder footing the bill.
Health Impacts
- Fentanyl-involved overdose deaths rose 22% from 2021 to 2022, totaling 73,838 in the U.S.
- Opioid use disorder led to 81,806 overdose deaths in the U.S. in 2022
- Methamphetamine-involved overdose deaths increased to 36,466 in the U.S. in 2022
- Cocaine overdose deaths reached 27,569 in the U.S. in 2022, up 8% from prior year
- Alcohol contributes to 178,000 annual deaths in the U.S., including 49% of liver disease deaths
- Cannabis use associated with 22% increased risk of schizophrenia in genetically predisposed youth
- Heroin injection leads to HIV infection in 9% of U.S. users annually without prevention
- Benzodiazepine misuse triples risk of opioid overdose death, per U.S. studies
- Chronic methamphetamine use causes 40-50% dopamine transporter loss in brain scans
- MDMA use linked to 3.2-fold increase in depression risk long-term
- Prescription opioid misuse initiates 80% of heroin users' opioid journeys in U.S.
- Inhalant abuse causes sudden death in 100-125 U.S. teens annually via cardiac arrhythmia
- Kratom overdose deaths rose to 1,805 in the U.S. from 2017-2021, often polydrug
- LSD rarely causes direct overdose but flashbacks persist in 20% of heavy users
- U.S. drug overdose deaths totaled 109,680 in 2023, 75% involving synthetic opioids like fentanyl
Health Impacts Interpretation
It appears we are hosting a grim Olympics where the medals are measured in body counts and the only record we keep breaking is our own national tragedy.
Legal and Policy
- U.S. federal drug arrests totaled 1.2 million in 2022, mostly possession
- 42 U.S. states legalized medical cannabis by 2023, covering 93% population
- DEA Schedule I drugs include heroin, LSD, marijuana, ecstasy per Controlled Substances Act
- Global opium production hit 6,800 tons in 2022, mainly Afghanistan
- U.S. opioid prescribing declined 44% from 2011 peak to 2022
- 24 states have decriminalized small amounts of drugs as of 2023
- Fentanyl declared Schedule I, but analogs challenge enforcement
- International treaties like 1961 UN Single Convention control 330 drugs
- U.S. spends $47 billion yearly on drug law enforcement
- Portugal's 2001 decriminalization reduced overdose deaths by 80% per capita
- Cannabis legalization in Canada led to 35% drop in illegal market share by 2022
- Methamphetamine precursors like pseudoephedrine regulated under Combat Meth Act 2005
- Psychedelic therapy legalization efforts: Oregon Measure 109 passed 2020 for psilocybin
- U.S. needle exchange programs operate in 37 states despite federal restrictions
- Global cocaine seizures: 1,400 tons in 2022, led by Colombia
Legal and Policy Interpretation
The American legal landscape presents a bizarre contradiction, where a person can be federally arrested for possessing a plant that their state not only sells in stores but also prescribed by their doctor, all while our enforcement spending soars despite evidence that treating drugs as a health issue saves lives.
Prevalence and Usage
- In 2022, 70.4 million people aged 12 or older (24.9% of the U.S. population) reported past year misuse of prescription pain relievers
- Globally, 296 million people used cannabis in 2021, representing 5.8% of the adult population aged 15-64
- In the United States, 48.7 million people aged 12 or older (17.3%) used illicit drugs in the past year in 2022
- Lifetime prevalence of cocaine use among U.S. adults aged 12+ reached 22.8 million people (8.1%) in 2022
- Methamphetamine use disorder affected 2.5 million people worldwide in 2019
- In Europe, 8.4 million adults aged 15-64 reported past-year cannabis use in 2022
- Heroin use in the past year was reported by 828,000 U.S. individuals aged 12+ in 2022
- Amphetamine-type stimulants were used by 34 million people globally in 2021 (0.7% of adults 15-64)
- Past-month hallucinogen use among U.S. youth aged 12-17 was 1.1% (289,000 people) in 2022
- Inhalant misuse in the past year affected 2.3 million U.S. people aged 12+ (0.8%) in 2022
- Sedative misuse past year prevalence was 5.4 million (1.9%) among U.S. adults 12+ in 2022
- Ecstasy/MDMA past-year use: 2.7 million U.S. people aged 12+ (1.0%) in 2022
- Kratom use in past year: 1.7 million U.S. adults 12+ (0.6%) in 2022
- LSD past-year use: 0.9 million U.S. people 12+ (0.3%) in 2022
- Past-month alcohol use disorder affected 28.9 million U.S. people 12+ (10.2%) in 2022
- Nicotine vaping past-month use among U.S. high school students: 10.0% in 2023
Prevalence and Usage Interpretation
Our collective preoccupation with the substances we prohibit often distracts from the more pervasive, and often legally sanctioned, tragedies of alcohol and nicotine, revealing a society curiously adept at fighting some addictions while quietly drowning in others.
Sources & References
- Reference 1NIDAnida.nih.govVisit source
- Reference 2UNODCunodc.orgVisit source
- Reference 3SAMHSAsamhsa.govVisit source
- Reference 4WHOwho.intVisit source
- Reference 5EMCDDAemcdda.europa.euVisit source
- Reference 6CDCcdc.govVisit source
- Reference 7THELANCETthelancet.comVisit source
- Reference 8NCBIncbi.nlm.nih.govVisit source
- Reference 9DEAdea.govVisit source
- Reference 10KFFkff.orgVisit source
- Reference 11SHRMshrm.orgVisit source
- Reference 12ACLUaclu.orgVisit source
- Reference 13NATUREnature.comVisit source
- Reference 14BJSbjs.govVisit source
- Reference 15SENTENCINGPROJECTsentencingproject.orgVisit source
- Reference 16OJPojp.govVisit source
- Reference 17CATOcato.orgVisit source
- Reference 18CANADAcanada.caVisit source
- Reference 19OREGONoregon.govVisit source
- Reference 20NASAnasa.orgVisit source